These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 16013437)

  • 1. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
    Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
    Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts.
    Zhang W; St Clair D; Butterfield A; Vore M
    Toxicol Sci; 2016 May; 151(1):44-56. PubMed ID: 26822305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
    Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
    Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
    PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
    Kim KH; Oudit GY; Backx PH
    J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
    Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
    Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction.
    Miyata M; Suzuki S; Misaka T; Shishido T; Saitoh S; Ishigami A; Kubota I; Takeishi Y
    PLoS One; 2013; 8(12):e79093. PubMed ID: 24391705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice.
    Nozaki N; Shishido T; Takeishi Y; Kubota I
    Circulation; 2004 Nov; 110(18):2869-74. PubMed ID: 15505089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice.
    Deng J; Coy D; Zhang W; Sunkara M; Morris AJ; Wang C; Chaiswing L; St Clair D; Vore M; Jungsuwadee P
    J Pharmacol Exp Ther; 2015 Nov; 355(2):272-9. PubMed ID: 26354996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity.
    Terrand J; Xu B; Morrissy S; Dinh TN; Williams S; Chen QM
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):102-10. PubMed ID: 21920376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest.
    Venkatakrishnan CD; Dunsmore K; Wong H; Roy S; Sen CK; Wani A; Zweier JL; Ilangovan G
    Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1736-44. PubMed ID: 18263706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice.
    Thandavarayan RA; Watanabe K; Sari FR; Ma M; Lakshmanan AP; Giridharan VV; Gurusamy N; Nishida H; Konishi T; Zhang S; Muslin AJ; Kodama M; Aizawa Y
    Free Radic Biol Med; 2010 Nov; 49(9):1422-31. PubMed ID: 20705132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice.
    Mizuta Y; Tokuda K; Guo J; Zhang S; Narahara S; Kawano T; Murata M; Yamaura K; Hoka S; Hashizume M; Akahoshi T
    Life Sci; 2020 Sep; 257():118074. PubMed ID: 32673667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
    Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
    Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart.
    Volkova M; Palmeri M; Russell KS; Russell RR
    Cardiovasc Res; 2011 May; 90(2):305-14. PubMed ID: 21233252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
    Chen J; Wei J; Xia P; Liu Y; Belew MD; Toohill R; Wu BJ; Cheng Z
    Cardiovasc Res; 2024 Jul; 120(9):1024-1036. PubMed ID: 38646672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
    Koka S; Das A; Zhu SG; Durrant D; Xi L; Kukreja RC
    J Pharmacol Exp Ther; 2010 Sep; 334(3):1023-30. PubMed ID: 20543097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.